SGCB and Parkinson disease: Studies performed in animal models of PD with a sGC inhibitor, ODQ 1 (Fig. 1), have shown that the enzyme could be a new drug target for restoring basal ganglia dysfunction and attenuating motor symptoms associated with PD.9